Designation / Description FHCR-1-2075/FH 4 MOUSE HYBRIDOMA
U.S. Patent Number
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Animals were immunized with glycolipids adsorbed to Salmonella minnesota.
Spleen cells were fused with Sp2/0 myeloma cells.
The antibody is specific for di- and tri- fucosylated type 2 chain glycolipids, but does not react with monofucosylated type 2 chains.
A feeder layer of mouse peritoneal macrophages or X-irradiated STO cells (see ATCC 56-X) is necessary for successful initiation of a culture from a thawed ampule.
Shipped frozen
Disclosure This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished.
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation

Hakomori SI. Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain. US Patent 4,876,199 dated Oct 24 1989

Ochi T, et al. The presence of a myeloid cell population showing strong reactivity with monoclonal antibody directed to difucosyl type 2 chain in epiphyseal bone marrow adjacent to joints affected with rheumatoid arthritis (RA) and its absence in the corresponding normal and non-RA bone marrow. J. Rheumatol. 15: 1609-1615, 1988. PubMed: 3236296